TRAVELING THE WORLD, WRITING WHAT THE PEOPLE NEED TO KNOW.
TRAVELING THE WORLD, WRITING WHAT THE PEOPLE NEED TO KNOW.
One of the most reviled companies in the United States recently gave Americans yet another reason to distrust their power: A recent Goldman Sachs report reveals the company questioning whether or not curing chronic illness is compatible with a sustainable business model. In an internal report viewed by CNBC about the potential of the biotech industry and gene therapy Read More…
Following another alleged chemical weapons attack in Syria, U.S. government officials are continuing to ramp up their rhetoric against the Assad regime. Though President Trump campaigned on a platform of scaling back America’s penchant for nation-building — and previously scolded President Obama for attempting to intervene in Syria — his administration continues to insinuate it Read More…
Google made headlines last month when it was announced it was partnering with the Pentagon to develop artificial intelligence for use in drones flown over war zones. The move divided the company, and this week, internal documentation of that conflict became available to the public in a petition signed by thousands of employees to the company’s CEO, Sundar Pichai, Read More…
While the nation remained fixated on gun control and Facebook’s violative practices last week, the U.S. government quietly codified the CLOUD Act, its own intrusive policies on citizens’ data. While the massive, $1.2 trillion omnibus spending bill passed Friday received widespread media attention, the CLOUD Act — which lawmakers snuck into the end of the 2,300-page Read More…
Every time a mass shooting rocks the United States, Americans demand their government do something. Whether it’s confiscating guns, arming teachers, or turning schools into prisons, neither politicians or the public can agree upon a solution to the ongoing violence, but they know their government should act. With last month’s Valentine’s Day shooting in Parkland, Florida, most Read More…
Despite increasing evidence that CBD (cannabidiol), a nonpsychoactive cannabinoid, can help treat severe seizure disorders, a thirteen-year-old Virginia boy suffering from a rare disease has been denied treatment for his use of the plant. Kaden Hartman suffers from Niemann-Pick disease, also dubbed “Child Alzheimer’s.” According to the National Niemann-Pick Foundation, it is a rare disorder that affects lysosomal storage and Read More…